RxDoctor Payments DataLook up a doctor →

Halden Ford, MD

Dermatology · Paducah, KYNPI 1396747846

Payments from drug & device makers

$8,617in general payments, 2019–2025

Across 486 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Novartis$1K
  • Regeneron Healthcare Solutions, Inc.$708
  • Pfizer$557
  • Sun Pharmaceutical Industries Inc.$514
  • plus $3K from 20 others

What the payments were for

  • Speaking & faculty fees$210%
  • Food & beverage$8,01393%
  • Education$5837%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,617 in reported general payments places this provider in the 70th percentile of 128 dermatology providers in Kentucky.

See all dermatology providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,518,178
Medicare patients
3,113
Services billed
18,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa20$417,287
Taltz AutoinjectorIxekizumab39$248,093
TremfyaGuselkumab17$225,325
Dupixent PenDupilumab58$217,269
Dupixent SyringeDupilumab49$205,701
Humira(Cf) PenAdalimumab14$185,903
RinvoqUpadacitinib18$115,010
Cosentyx Unoready PenSecukinumab11$114,688
Taltz SyringeIxekizumab12$82,279
Humira(Cf)Adalimumab12$74,266
OtezlaApremilast13$62,712
Fluorouracil188$14,062
Clobetasol Propionate242$9,041
Fluocinonide141$4,638
Ketoconazole252$4,241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,274$225,32517 claims
AbbVieRinvoq, Humira(Cf)$1,783$189,27630 claims
AmgenOtezla$411$62,71213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 128 dermatology providers in Kentucky.

Other dermatology in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →